drugset / Trial / NCT04452136
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
Expanded access
Approved for marketing
Jeanne Link
OHSU Center of Radiochemistry Research · collabOHSU Knight Cancer Institute · collabOregon Health and Science University · collab
Summary
This study provides expanded access to radiotracer Gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA)-HBED-CC (68Ga-PSMA-11) with Positron Emission Tomography (PET) imaging for participants with intermediate and high risk prostate cancer before prostatectomy or for suspected biochemical recurrence of their prostate cancer. Compared to conventional imaging, 68Ga PSMA-HBED-CC might improve the ability to localize the sites of recurrent or metastatic disease, which helps with surgical and other treatment planning.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 259 mbq | Intravenous |